Ramathibodi Laser Center, Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
J Cosmet Dermatol. 2022 May;21(5):2031-2037. doi: 10.1111/jocd.14765. Epub 2022 Jan 23.
Epidermal growth factor (EGF) may promote wound healing and decrease laser-induced postinflammatory hyperpigmentation (PIH).
To evaluate the effectiveness of an EGF-containing cream on PIH, post-laser erythema, and transepidermal water loss (TEWL) after 1,064-nm Q-Switched Nd: YAG laser treatment of Hori's nevus.
This is a split-face, double-blinded, randomized, controlled study conducted in 30 subjects with bilateral Hori's nevus. After laser treatment, participants were randomized to apply EGF cream on one facial side and placebo on the other side for 8 weeks. The incidence and intensity of PIH were assessed by photographs and melanin indexes (MIs) ratio at baseline, Week 2, Week 4, and Week 8. Post-laser erythema and TEWL were measured at baseline, Day 1, Day 3, and Day 7. Side effects and patient satisfaction score were evaluated.
The incidence of PIH was 26.7% in EGF group compared to 20% in placebo. The intensity of PIH was 0.057 (0.033-0.086) and 0.045 (0.027-0.076) in EGF and placebo group, respectively. There was no significant difference in both incidence (p = 0.5) and intensity of PIH (p = 0.145). Post-laser erythema was not statistically different between groups. EGF could alleviate TEWL better than placebo but without statistical significance. Patient satisfaction score was significantly higher in EGF group compared to placebo (p < 0.001).
The EGF-containing cream could not prevent PIH. It may reduce laser-induced skin barrier damage. Future studies in more subjects are needed.
表皮生长因子(EGF)可能促进伤口愈合并减少激光诱导的炎症后色素沉着过度(PIH)。
评估含 EGF 的乳膏对 Hori 痣 1064nm Q-开关 Nd:YAG 激光治疗后 PIH、激光后红斑和经表皮水分流失(TEWL)的疗效。
这是一项在 30 名双侧 Hori 痣患者中进行的分割面、双盲、随机、对照研究。激光治疗后,将参与者随机分为 EGF 乳膏组和安慰剂组,分别在一侧面部使用 8 周。在基线、第 2 周、第 4 周和第 8 周通过照片和黑色素指数(MI)比值评估 PIH 的发生率和强度。在基线、第 1 天、第 3 天和第 7 天测量激光后红斑和 TEWL。评估不良反应和患者满意度评分。
EGF 组 PIH 的发生率为 26.7%,安慰剂组为 20%。EGF 组和安慰剂组 PIH 的强度分别为 0.057(0.033-0.086)和 0.045(0.027-0.076)。两组 PIH 的发生率(p=0.5)和强度(p=0.145)均无统计学差异。两组间激光后红斑无统计学差异。EGF 组 TEWL 改善优于安慰剂组,但无统计学意义。EGF 组患者满意度评分明显高于安慰剂组(p<0.001)。
含 EGF 的乳膏不能预防 PIH。它可能减轻激光引起的皮肤屏障损伤。需要在更多的受试者中进行进一步的研究。